| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | 35,390 | 44,530 | 35,720 | 49,000 | 67,300 |
| Sales Growth | -20.53% | +24.66% | -27.10% | -27.19% | +4.83% |
| Net Income | -26,570 | -46,810 | -65,550 | -36,600 | -9,760 |
| Net Income Growth | +43.24% | +28.59% | -79.10% | -275.00% | +12.47% |
Aegerion Pharma Inc (AEGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.
Fiscal Year End Date: 12/31